Pembrolizumab is an anti-PD-1 antibody that improved overall survival (OS) for metastatic NSCLC in the second-line setting after platinum-doublet chemotherapy1 and for treatment-naive tumors with PD-L1 expression of ≥50% or ≥1%.2,3 Pembrolizumab has also demonstrated OS improvements in combination with platinum-doublet chemotherapy, regardless of PD-L1 status.4,5 The optimal chemotherapy backbone for combination with immunotherapy is unknown. Here, CD274 is linked to non-small cell lung carcinoma.